| REZOLUTE INC. NEW DL-,001 |
| USA |
| Gesundheit |
| US76200L3096 / A2QEWP |
| 6HV1 (Frankfurt) / RZLT (NASDAQ) |
| FRA:6HV1, ETR:6HV1, 6HV1:GR, NASDAQ:RZLT |
| - |
| https://rezolutebio.com/ |
|
Rezolute, Inc. is a late-stage rare disease company focused on developing therapies to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism, including congenital and tumor forms. Its lead clinical asset, ersodetug, is an intra..
>Volltext.. |
| 235.82 Mio. EUR |
| 124.72 Mio. EUR |
| - |
| -77.71 Mio. EUR |
| -72.83 Mio. EUR |
| -0.8 EUR |
| 1.11 Mio. EUR |
| 10.33 Mio. EUR |
| -66.71 Mio. EUR |
| 13.95 |
| - |
| -4.37% |
| - |
| - |
| - |
| REZOLUTE |
| 02.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|